Tesamorelin
egrifta
GHRH analog — visceral-fat reduction. FDA-approved for HIV lipodystrophy. Protocol with measurable markers.
- Half-life
- 30 min
- Out of system
- ~3 h
- Route
- Subcutaneous
- Level
- Intermediate
Very short-acting — protocols dose 1–2× a day. After the last dose, roughly 97% has cleared in ~3 h (five half-lives) — the window that matters for washouts, bloodwork and surgery.
What Tesamorelin is used for
- GHRH analog approved for HIV lipodystrophy — proven visceral-fat reduction
- Cleanest GH-axis intervention with regulatory backing
- Reported sleep + recovery improvements
How it's typically used
Approved: 1–2 mg subcutaneous daily, evening dose.
What to watch for
- IGF-1 rise can affect glucose and joint comfort
- Avoid with active cancer or pituitary issues
- Expensive; off-label use is unsupervised
About Performance & GH
- What they are
- Growth-hormone secretagogues and related performance compounds. Rather than supplying GH, they push your pituitary to release more of its own in a pulse.
- How they're run
- Subcutaneous injection, most often at night on an empty stomach so the pulse lands with natural sleep-driven GH release.
- What to watch
- Water retention, tingling hands, and hunger swings are the common early signs. Raising GH raises IGF-1 — worth tracking on bloodwork, and a reason to avoid these with any cancer history.
Full guide
Tesamorelin: A Tracking Guide for Visceral-Fat Protocols
What tesamorelin is, how protocols are structured, what to measure if you want to evaluate effects on visceral fat, energy, and sleep.
Other performance & gh
Peptid AI is an educational and self-tracking tool — not a medical service, and not a vendor. Nothing here is medical advice, a prescription, or an endorsement. Doses reflect what is commonly reported in research literature; they are not recommendations. Many compounds listed are experimental, not approved for human use, and/or controlled substances that are illegal to possess without a prescription in many countries. Always consult a qualified physician before starting, changing, or stopping any protocol.